A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 5, 2015, Pages E748-E756

  Plews, Robert L ^a   Yusof, Adlina Mohd ^a   Wang, Chaojie ^a   Saji, Motoyasu ^a   Zhang, Xiaoli ^c   Chen, Ching Shih ^a,b   Ringel, Matthew D ^a   Phay, John E ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b College of Pharmacy ^*  (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ENZYME ACTIVATOR; ENZYME INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; OSU 53; PHOSPHATASE; PROTEIN RET; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; OSU-53; PROTEIN KINASE INHIBITOR; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BRAF GENE; CANCER INHIBITION; CHROMOSOME 10; CHROMOSOME DELETION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; ONCOGENE; ONCOGENE RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER CELL LINE; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; PATHOLOGY; THYROID NEOPLASMS; TUMOR CELL LINE;

MAMMALIA; MUS MUSCULUS;

AMP-ACTIVATED PROTEIN KINASES; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SULFONAMIDES; THIAZOLIDINEDIONES; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84929378142     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1777     Document Type: Article

References (33)

1. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol. 2007;47:185-210.
2. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8:774-785.
3. Hardie DG, Sakamoto K. AMPK: a key sensor of fuel and energy status in skeletal muscle. Physiology (Bethesda). 2006;21:48-60.
4. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15-25.
5. Scott JW. Maintaining energy balance in health and disease: role of the AMP-activated protein kinase. Protein Rev. 2011;13:199-232.
6. Hardie DG, Scott JW, Pan DA, Hudson ER. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 2003;546:113-120.
7. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett. 2010;584:1287-1295.
8. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer. 2007;7:961-967.
9. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord. 2011;9:69-75.
10. Klubo-Gwiezdzinska J, Costello J Jr, Patel A, et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab. 2013;98:3269-3279.
11. Chen G, Xu S, Renko K, Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab. 2012;97:E510-E520.
12. Choi HJ, Kim TY, Chung N, et al. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside. J Endocrinol. 2011;211:79-85.
13. Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res. 2011;17:7511-7517.
14. Lee KH, Hsu EC, Guh JH, et al. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem. 2011;286:39247-39258.
15. Guh JH, Chang WL, Yang J, et al. Development of novel adenosine monophosphate-activated protein kinase activators. J Med Chem. 2010;53:2552-2561.
16. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275:223-228.
17. Sun Y, Connors KE, Yang DQ. AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner. Mol Cell Biochem. 2007;306:239-245.
18. Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93:4331-4341.
19. Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM, Paulin C. Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer. 1994;73:2206-2212.
20. Tanaka J, Ogura T, Sato H, Hatano M. Establishment and biological characterization of an in vitro human cytomegalovirus latency model. Virology. 1987;161:62-72.
21. Goretzki PE, Frilling A, Simon D, Roeher HD. Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res. 1990;118:48-63.
22. Gustavsson B, Hermansson A, Andersson AC, et al. Decreased growth rate and tumour formation of human anaplastic thyroid carcinoma cells transfected with a human thyrotropin receptor cDNA in NMRI nude mice treated with propylthiouracil. Mol Cell Endocrinol. 1996;121:143-151.
23. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63:4561-4567.
24. Carlsson J, Nilsson K, Westermark B, et al. Formation and growth of multicellular spheroids of human origin. Int J Cancer. 1983;31:523-533.
25. Ringel MD, Hayre N, Saito J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001;61:6105-6111.
26. Gottschalk PG, Dunn JR. The five-parameter logistic: a characterization and comparison with the four-parameter logistic. Anal Biochem. 2005;343:54-65.
27. Bonini MG, Gantner BN. The multifaceted activities of AMPK in tumor progression-why the "one size fits all" definition does not fit at all? IUBMB Life. 2013;65:889-896.
28. Faustino A, Couto JP, Populo H, et al. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:E1139-E1149.
29. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Dual inhibition of mitogen-activated protein kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009;94:4107-4112.
30. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res. 2011;17:6482-6489.
31. Liu D, Xing J, Trink B, Xing M. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer. 2010;127:2965-2973.
32. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKα energy sensor pathway by growth factors and oncogenic BRAF. PLoS One. 2009;4:e4771.
33. Malaguarnera R, Chen KY, Kim TY, et al. 2014 Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. J Clin Endocrinol Metab. 2014;99(10):E1976-E1987.